Trial Profile

Randomized, Double Blind, Active-controlled, Parallel Study to Analyse Effects of the Combination of Aliskiren and Valsartan on the Vascular Structure and Function of Retinal Vessels

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Nov 2016 Results assessing effect of Valsartan on retinal capillary rarefaction in hypertensive patients (n=150) using patients data from this and other two trials (NCT00152698 and NCT01319344) published in the Journal of Clinical Hypertension (Greenwich)
05 Aug 2015 New trial record
15 Jun 2015 Primary endpoint has been met. (To investigate the combined effect of aliskiren and valsartan on vascular structure, assessed by wall to lumen ratio of retinal arterioles, in hypertensive patients.), according to an abstract presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com